🇪🇺 Daurismo in European Union

EMA authorised Daurismo on 26 June 2020

Marketing authorisation

EMA — authorised 26 June 2020

  • Application: EMEA/H/C/004878
  • Marketing authorisation holder: Pfizer Europe MA EEIG
  • Local brand name: Daurismo
  • Indication: Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
  • Pathway: orphan
  • Status: approved

Read official source →

Daurismo in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Daurismo approved in European Union?

Yes. EMA authorised it on 26 June 2020.

Who is the marketing authorisation holder for Daurismo in European Union?

Pfizer Europe MA EEIG holds the EU marketing authorisation.